MyCellHub — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2018 in Ghent, Belgium, MyCellHub positioned itself as a specialized software provider for the high-growth cell and gene therapy sector. Its core product was a modular, cloud-based MES aimed at streamlining complex, manual, and compliance-heavy biomanufacturing processes. The company's recent acquisition and integration into Title21 Health Solutions indicates a strategic move to scale its technology within a larger digital health ecosystem, transitioning from a standalone product to a component of a comprehensive suite for advanced therapy manufacturing.

Cell TherapyDigital Health

Technology Platform

Cloud-based, modular Manufacturing Execution System (MES) software designed specifically for GMP-compliant cell and gene therapy manufacturing. Modules include electronic batch records, cleaning management, and environmental monitoring.

Opportunities

The rapid expansion of the cell and gene therapy market creates a direct and growing demand for specialized manufacturing software.

Integration into Title21 provides a larger platform, broader distribution, and the ability to offer a more comprehensive digital suite, moving beyond a point-solution MES to become part of the central operating system for advanced therapy manufacturers.

Risk Factors

Key risks include operational and technological integration challenges post-acquisition into Title21, potential loss of focus or agility as part of a larger entity, and intense competition from both established enterprise software vendors and agile startups targeting the same niche CGT manufacturing space.

Competitive Landscape

MyCellHub competed in the specialized MES segment for advanced therapies. Competitors include purpose-built startups (e.g., Vineti, Cognizant's Cell and Gene Therapy Suite) and modules from large industrial automation and PLM companies (e.g., Siemens Opcenter, Dassault Systèmes' BIOVIA). Its acquisition by Title21 positions it against other comprehensive digital platform providers serving the pharma and biotech industry.

More companies in Digital Health & Biotech SaaS →More companies in Belgium →